Millennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Millennium Management LLC raised its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 417.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 76,829 shares of the company's stock after purchasing an additional 61,994 shares during the period. Millennium Management LLC owned 0.15% of Stoke Therapeutics worth $847,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of STOK. JPMorgan Chase & Co. boosted its holdings in shares of Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after buying an additional 4,512 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $1,423,000. Bank of New York Mellon Corp boosted its holdings in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after buying an additional 1,330 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after buying an additional 2,787 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $113,000.

Analyst Ratings Changes

STOK has been the subject of several research analyst reports. Chardan Capital restated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of "Buy" and an average price target of $23.20.

Insider Activity

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,748 shares of company stock worth $225,687 in the last 90 days. 11.30% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Stock Performance

STOK stock opened at $11.14 on Friday. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $17.58. The stock has a market capitalization of $608.21 million, a PE ratio of -5.30 and a beta of 1.20. The company has a fifty day moving average of $8.77 and a 200-day moving average of $9.66.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Equities analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.